The KD Pharma Group has acquired the manufacturing assets of the former Rohner AG. The assets give KD Pharma access to new complementary technologies that will allow the company to further expand its pharmaceutical CDMO business. In addition, KD Pharma has strengthened its CDMO team by hiring several key personnel from the former Rohner team.   “KD Pharma has all the technology, capacity, and people to become an even larger player in the CDMO market,” said Oscar Groet, CEO of the KD Pharma Group...